CapsoVision, Inc.
CVHealthcareNASDAQMedical Devices
Scan Results
Daily timeframeHeadquartered within the healthcare sector, CapsoVision, Inc. focuses on Medical Devices services and products. CapsoVision, Inc., a medical technology company, manufactures and markets endoscopic video imaging devices focused on internal imaging of the gastrointestinal system. With a market capitalization of $338.8M, it sits in small-cap territory. The company offers CapsoCam Plus, a capsule endoscopy system for visualization of the small bowel mucosa in adults and children aged 2 years and above; and CapsoCam Colon for visualization of the colon and detection and measurement of polyps, as well as develops CapsoColon 3D for large intestines (colon).
Market Cap
$338.8M
Beta
—
P/E (TTM)
—
P/E (Fwd)
—
EPS (TTM)
$-1.06
EPS (Fwd)
—
ROE
-185.1%
ROA
-88.1%
Cash
$17.9M
Total Debt
$788,000
Free CF
-$13.2M
52W Change
93.7%
Annual Financials
Cash vs Debt
CapsoVision, Inc. holds $17.9M in cash against $788K in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company is burning cash, with free cash flow at -$13.2M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -185.1% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $9.8M (2023) to $13.6M (2025), reflecting a 39% increase over the period.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing CV.